comparemela.com

Latest Breaking News On - Cell biology unit - Page 8 : comparemela.com

Sinopharm: Over 95% develop antibody responses - J pura research

Tuesday, 20 July 2021 - 8:20 The Allergy, Immunology & Cell Biology Unit of the Sri Jayawardanapura University has investigated immune responses to the Sinopharm vaccine and have found that the vaccine induced antibody responses in over 95% of individuals in Sri Lanka, similar to levels seen following natural COVID-19 illness. The Sinopharm vaccine was found very effective for the Delta variant as well. The antibody responses to delta variant and neutralizing antibodies, were similar to levels seen following natural infection according to Prof Neelika Malawige and Dr. Chandima Jeewandara.  Click here for the report Full Report The report on the Sri Jayawardanapura University website says the following;

Nineteen more Delta cases detected in Sri Lanka; officials warn of possible rapid spread

Nineteen more Delta cases detected in Sri Lanka; officials warn of possible rapid spread
economynext.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from economynext.com Daily Mail and Mail on Sunday newspapers.

Sri Lanka detects first community case of Delta variant of coronavirus

Sri Lanka detects first community case of Delta variant of coronavirus PTI Updated Jun 18, 2021, 1:31 pm IST Sri Lanka s COVID-19 vaccination began in late January with India s gift of 500,000 Covishield AstraZeneca vaccines  Sri Lankan health officials collect swab samples from people to test for the coronavirus in Colombo, Sri Lanka, June 10, 2021. (AP/Eranga Jayawardena) Colombo: Sri Lankan authorities have said that the highly transmissible Delta variant of COVID-19 has been detected for the first time in the community. Chandima Jeewandara of the University of Sri Jayawardenapura here said the strain was detected in samples collected from an area in the Colombo central suburb of Dematagoda.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.